State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, China.
Department of Laboratory Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510080, China.
Virol Sin. 2022 Oct;37(5):716-723. doi: 10.1016/j.virs.2022.06.006. Epub 2022 Jun 25.
Human adenoviruses type 26 (HAdV26) and type 35 (HAdV35) have increasingly become the choice of adenovirus vectors for vaccine application. However, the population pre-existing immunity to these two adenoviruses in China, which may reduce vaccine efficacy, remains largely unknown. Here, we established micro-neutralizing (MN) assays to investigate the seroprevalence of neutralizing antibodies (nAbs) against HAdV26 and HAdV35 in the general population of Guangdong and Shandong provinces, China. A total of 1184 serum samples were collected, 47.0% and 15.8% of which showed HAdV26 and HAdV35 nAb activity, respectively. HAdV26-seropositive individuals tended to have more moderate nAbs titers (201-1000), while HAdV35-seropositive individuals appeared to have more low nAbs titers (72-200). The seropositive rates of HAdV26 and HAdV35 in individuals younger than 20 years old were very low. The seropositive rates of HAdV26 increased with age before 70 years old and decreased thereafter, while HAdV35 seropositive rates did not show similar characteristics. Notably, the seropositive rates and nAb levels of both HAdV26 and HAdV35 were higher in Guangdong Province than in Shandong Province, but did not exert significant differences between males and females. The seroprevalence between HAdV26 and HAdV35 showed little correlation, and no significant cross-neutralizing activity was detected. These results clarified the characteristics of the herd immunity against HAdV26 and HAdV35, and provided information for the rational development and application of HAdV26 and HAdV35 as vaccine vectors in China.
人腺病毒 26 型（HAdV26）和 35 型（HAdV35）已逐渐成为腺病毒疫苗载体的选择。然而，中国人群对这两种腺病毒的预先存在的免疫，可能会降低疫苗的效果，这在很大程度上仍然未知。在这里，我们建立了微量中和（MN）测定法，以调查中国广东和山东两省普通人群中针对 HAdV26 和 HAdV35 的中和抗体（nAb）的血清流行率。共收集了 1184 份血清样本，其中 47.0%和 15.8%分别显示出 HAdV26 和 HAdV35 nAb 活性。HAdV26 血清阳性者的中和抗体滴度往往更高（201-1000），而 HAdV35 血清阳性者的中和抗体滴度较低（72-200）。20 岁以下个体的 HAdV26 和 HAdV35 的血清阳性率非常低。HAdV26 的血清阳性率在 70 岁之前随年龄增长而增加，此后降低，而 HAdV35 的血清阳性率则没有显示出类似的特征。值得注意的是，HAdV26 和 HAdV35 的血清阳性率和 nAb 水平在广东省均高于山东省，但在男性和女性之间没有显著差异。HAdV26 和 HAdV35 之间的血清流行率相关性不大，也没有检测到显著的交叉中和活性。这些结果阐明了针对 HAdV26 和 HAdV35 的群体免疫特征，为合理开发和应用 HAdV26 和 HAdV35 作为中国疫苗载体提供了信息。
